- Issuer
- Global X
- Inception Date
- Nov 2, 2021
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- Global X Genomics & Biotechnology UCITS ETF
- Distribution Policy
- Accumulating
- Asset Class
- Equity
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GNOM.L Performance Chart
Global X Genomics & Biotechnology UCITS ETF (GNOM.L) is up 22.1% since the beginning of the year. GNOM.L is currently trading at $10 per share.
Loading charts...
Returns By Period
Global X Genomics & Biotechnology UCITS ETF (GNOM.L) has returned 22.10% so far this year and 62.79% over the past 12 months.
Global X Genomics & Biotechnology UCITS ETF
- 1D
- -0.17%
- 1M
- 11.69%
- 6M
- 15.71%
- YTD
- 22.10%
- 1Y
- 62.79%
- 3Y*
- 4.58%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.38%
- 1M
- 0.24%
- 6M
- 9.32%
- YTD
- 10.62%
- 1Y
- 21.28%
- 3Y*
- 18.90%
- 5Y*
- 11.84%
- 10Y*
- 13.36%
GNOM.L Monthly Returns History
Based on dividend-adjusted daily data since Nov 2, 2021, GNOM.L's average daily return is -0.02%, while the average monthly return is -0.41%.
Historically, 46% of months were positive and 54% were negative. The best month was Nov 2023 with a return of +19.8%, while the worst month was Jan 2022 at -20.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, GNOM.L closed higher 46% of trading days. The best single day was Dec 14, 2023 with a return of +9.2%, while the worst single day was May 9, 2022 at -7.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.17% | -0.12% | -9.78% | 5.48% | 9.03% | 14.98% | -1.65% | 22.10% | |||||
| 2025 | 6.43% | -11.26% | -12.85% | 1.60% | -4.02% | 9.11% | 4.01% | 3.53% | 4.81% | 18.05% | 2.26% | -0.00% | 19.30% |
| 2024 | -7.43% | 11.27% | -5.94% | -13.00% | 3.27% | 1.38% | 11.82% | -2.92% | -0.75% | -6.81% | 3.52% | -10.59% | -17.99% |
| 2023 | 7.73% | -6.26% | -3.77% | 0.05% | -1.27% | 0.99% | 0.82% | -7.75% | -10.03% | -13.37% | 19.77% | 11.95% | -5.77% |
| 2022 | -20.93% | -0.52% | -3.17% | -14.09% | -7.87% | 1.32% | 15.96% | -2.36% | -6.91% | 3.03% | -3.12% | -2.27% | -37.21% |
| 2021 | -7.08% | -1.63% | -8.59% |
Benchmark Metrics
Global X Genomics & Biotechnology UCITS ETF has an annualized alpha of -11.99%, beta of 0.71, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since November 02, 2021.
- This ETF participated in 161.41% of S&P 500 Index downside but only 87.24% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this ETF moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -11.99%
- Beta
- 0.71
- R²
- 0.13
- Upside Capture
- 87.24%
- Downside Capture
- 161.41%
Expense Ratio
GNOM.L has an expense ratio of 0.50%, placing it in the medium range.
Return for Risk
Risk / Return Rank
GNOM.L ranks 77 for risk / return — better than 77% of ETFs on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF (GNOM.L) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GNOM.L | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.42 | ||
| Sortino ratioReturn per unit of downside risk | +0.63 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.31 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 3.35 | 2.35 | +1.00 |
| Martin ratioReturn relative to average drawdown | 9.16 | 10.19 | -1.03 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Global X Genomics & Biotechnology UCITS ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Global X Genomics & Biotechnology UCITS ETF was 69.32%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Global X Genomics & Biotechnology UCITS ETF drawdown is 37.11%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-69.32%Apr 2025 | 3y 5mo | — | 4y 8moNov 2021 - now | 2025 selloff2025 |
-0.51%Nov 2021 | 0s | 3d | 3dNov 2021 - Nov 2021 | — |
Drawdown Indicators
| GNOM.L | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.32% | -56.78% | -12.54% |
Max Drawdown (1Y)Largest decline over 1 year | -18.91% | -9.10% | -9.81% |
Max Drawdown (3Y)Largest decline over 3 years | -44.77% | -18.90% | -25.87% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -37.11% | -0.49% | -36.62% |
Average DrawdownAverage peak-to-trough decline | -47.16% | -10.70% | -36.46% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.92% | 2.09% | +4.83% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with GNOM.L
Add Global X Genomics & Biotechnology UCITS ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GNOM.L